Highlights

  • Memphasys has received a 1,000-unit Felix cartridge order from MENA distributor ITL, covering Qatar, UAE, and Kuwait, bringing confirmed ITL orders to 1,800 of the 2,500-cartridge annual minimum in less than two full quarters
  • Hamad Medical Corporation, Qatar's largest IVF institution, has ordered a second Felix console — a commitment that will double its Felix throughput capacity and signal institutional adoption beyond trial-phase utilisation
  • UAE and Kuwait have transitioned from initial evaluations to committed procurement, with Turkey expected to commence orders in July 2026 pending regulatory registration, and additional MENA markets including Egypt, Bahrain, and Jordan to follow

 

Memphasys Limited (ASX:MEM) is a reproductive biotechnology company that has spent several years developing and commercialising the Felix System — a patented bio-separation technology designed to select viable sperm cells for assisted reproduction procedures. The technology combines electrophoresis and size-exclusion membranes to deliver a faster, gentler, and more standardised sperm selection process that replaces conventional centrifugation, which can cause cellular stress and DNA damage.

The commercial story accelerated materially following CE Mark approval and the establishment of an exclusive MENA distribution agreement with International Technical Legacy (ITL). The latest order update, released on 27 May 2026, reflects a MENA commercial rollout that appears to be tracking ahead of the pace that the distribution agreement requires.

MEM shares traded 25% higher at AUD 0.005 per share on 27 May. 

The ITL Order and What It Signals

ITL's 1,000-cartridge order covers three markets: Qatar, UAE, and Kuwait. The Qatar component reflects the continuation of the clinical program at Hamad Medical Corporation, which began in early 2026, as well as the commencement of at least one new clinic in the country. The UAE and Kuwait orders represent conversion from trial evaluations to committed procurement — a transition that is commercially more significant than the initial cartridge volumes suggest.

The decision by HMC to order a second Felix console is the most consequential element of the announcement. HMC is Qatar's primary public health provider and serves as the anchor institutional reference customer for the MENA rollout. A second console Investment doubles the Facility's Felix throughput capacity and indicates that Felix has passed the threshold from clinical evaluation to operational integration. For other fertility institutions in the region assessing adoption decisions, HMC's commitment provides a reference point that reduces the perceived risk of investment.

Order Trajectory Versus Contractual Minimum

The ITL distribution agreement requires the distributor to order a minimum of 2,500 Felix cartridges annually. With 1,800 cartridges confirmed in under two full quarters following CE Mark approval, ITL is tracking materially above the annualised pace required to meet that minimum. The remaining 700 cartridges needed to satisfy the annual minimum are expected to be covered by ongoing Demand across existing markets, the October delivery of 600 confirmed cartridges, and orders from Turkey and other markets expected later in 2026.

This trajectory matters for Memphasys because the company has structured its MENA commercialisation around a contracted Revenue base supported by the ITL minimum commitment. The early overperformance against that minimum, if sustained, suggests that the distributor is experiencing genuine clinical demand rather than managing inventory to meet contractual thresholds.

Turkey and Pipeline Markets

Turkey was added to the ITL distribution territory following CE Mark approval in September 2025. Local regulatory registration is expected imminently, with orders anticipated to commence in July 2026. Turkey is a significant fertility services market, with a large base of IVF clinics and a growing medical tourism segment. Its addition to the active order pipeline could represent a meaningful increase in Volume run-rate for the second half of 2026.

Beyond Turkey, the pipeline markets of Egypt, Bahrain, and Jordan are expected to place orders later in 2026 following regulatory registration in each Jurisdiction. The company has appointed six local commercial partners across UAE, Kuwait, Turkey, Egypt, Bahrain, and Jordan to work alongside ITL and Memphasys to accelerate sales in those markets. This network of sub-distributors or commercial agents suggests a deliberately constructed infrastructure for a geographically distributed rollout.

Broader Commercial and Pipeline Developments

Memphasys has indicated it is in advanced contract negotiations with several prospective new clients and partners across both new and existing jurisdictions. The company has not disclosed specific details but has flagged updates in due course. These developments suggest the company is pursuing growth outside the ITL MENA territory in parallel with the regional rollout.

The scalability of the Felix System — which operates through consumable cartridges and a Capital-equipment console — creates a Business model with Recurring Revenue characteristics. Once a console is placed in a fertility clinic, the ongoing demand for cartridges is driven by caseload rather than additional capital decision-making by the clinic. HMC's second console order reinforces the potential for volume growth within existing accounts.

Conclusion

Memphasys is demonstrating through consecutive order updates that the MENA commercialisation strategy is generating genuine clinical adoption rather than distributor inventory accumulation. The transition of UAE and Kuwait from evaluation to committed procurement, the second HMC console order, and the pipeline of regulatory approvals across additional markets collectively indicate that the Felix System is progressing through the adoption curve in its first major international distribution territory. The next operational milestones — Turkish orders in July, October deliveries, and the anticipated update on new client negotiations — will determine whether the order momentum of the first two quarters can be sustained through the second half of 2026.